Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus capecitabine maintenance versus capecitabine maintenance in recurrent/metastatic or persistent cervical cancer after chemoradiotherapy
ChiCTR1800017291Phase 2Recruiting
- Sponsor
- Guizhou Medical University
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib and capecitabine in Cervical Cancer (CC) (2 arms), sponsored by Guizhou Medical University. Primary endpoints: Progression-free survival and One-year survival rate. Started Jul 2018; status: recruiting.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800017291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017291.